Aardvark Therapeutics (AARD) Total Liabilities (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Total Liabilities data on file, last reported at $11.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 83.14% year-over-year to $11.6 million; the trailing twelve-month figure through Mar 2026 stood at $11.6 million (up 83.14% YoY), and the FY2025 full-year result was $10.5 million, up 95.55% from the prior year.
• Total Liabilities climbed to $11.6 million in Q1 2026, from $10.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $11.6 million in Q1 2026 to a low of $5.4 million in Q4 2024.
• A 3-year average of $9.2 million and a median of $10.5 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 95.55% in 2025 and jumped 83.14% in 2026, its largest moves.
• Tracing AARD's Total Liabilities over 3 years: stood at $5.4 million in 2024, then surged by 95.55% to $10.5 million in 2025, then gained by 10.01% to $11.6 million in 2026.
• Business Quant data shows AARD's Total Liabilities at $11.6 million in Q1 2026, $10.5 million in Q4 2025, and $10.9 million in Q3 2025.